Monoclonal Antibodies

Tiragolumab for B-Cell Lymphoma

Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, VA
Targeting 3 different conditionsTiragolumab +3 morePhase 1Waitlist AvailableResearch Sponsored by Genentech, Inc.

Study Summary

This trial is testing a new immunotherapy drug to see if it's safe and works well against certain blood cancers.

Eligible Conditions
  • B-Cell Lymphoma
  • Non-Hodgkin's Lymphoma
  • Multiple Myeloma

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have B-cell NHL that has come back or didn't respond to at least two previous treatments, and there are no other effective treatments available. You have at least one measurable lesion.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants With Adverse Events
Secondary outcome measures
Objective Response Rate (ORR) for R/R MM
Percentage of Participants With ADAs to Atezolizumab
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups
Experimental Treatment
Group I: Arm E: Tiragolumab + Atezolizumab + Daratumumab R/R MMExperimental Treatment3 Interventions
Participants with R/R MM will receive 600 mg tiragolumab Q3W + atezolizumab by IV infusion Q3W + daratumumab by SC injection.
Group II: Arm D: Tiragolumab + Rituximab R/R NHLExperimental Treatment2 Interventions
Participants with R/R NHL will receive 600 mg tiragolumab Q3W + rituximab by IV infusion and SC injection (optional).
Group III: Arm C: Tiragolumab + Daratumumab R/R MMExperimental Treatment2 Interventions
Participants with R/R MM will receive 600 mg tiragolumab Q3W + daratumumab by subcutaneous (SC) injection.
Group IV: Arm B: Tiragolumab R/R NHLExperimental Treatment1 Intervention
Participants with relapsed or refractory (R/R) non-Hodgkin Lymphoma (NHL) will receive a single dose of 600 mg tiragolumab by IV infusion Q3W.
Group V: Arm A: Tiragolumab R/R MMExperimental Treatment1 Intervention
Participants with relapsed or refractory (R/R) Multiple Myeloma (MM) will receive a single dose of 600 mg tiragolumab by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W).
First Studied
Drug Approval Stage
How many patients have taken this drug
Not yet FDA approved
FDA approved
FDA approved

Find a site

Who is running the clinical trial?

Genentech, Inc.Lead Sponsor
1,524 Previous Clinical Trials
566,068 Total Patients Enrolled
Clinical TrialsStudy Director
Hoffmann-La Roche
2,179 Previous Clinical Trials
884,643 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are eligible to join this clinical trial?

"Correct. indicates that the research was first published on July 22, 2019 and recently updated November 22, 2022. The trial is presently seeking 60 volunteers to be recruited across 7 sites."

Answered by AI

Is there a call for participants in this research endeavor?

"Aye, the details provided on appear to show that this medical trial is still accepting applicants. It was initiated on July 22nd 2019 and updated as recently as November 22nd 2022, with a total of 60 participants being recruited across 7 different research sites."

Answered by AI

Has Tiragolumab been accorded official clearance by the FDA?

"Due to limited data regarding its safety and efficacy, tiragolumab has been given a score of 1 on our scale. This is typical for phase 1 clinical trials."

Answered by AI

Have other research endeavors implemented Tiragolumab?

"Tiragolumab's first trial was conducted at the National Institutes of Health Clinical Centre in 1993. Since then, 959 trials have been completed and a further 905 are still recruiting participants, with Nashville, Tennessee being one of their main sites for research."

Answered by AI

Where are the most prominent locales for this trial in Canada?

"Patients may be enrolled in this medical study at SCRI located in Nashville, Tennessee; Oncology Hematology Care Inc. (OHC) of Cincinnati, Ohio; Colorado Blood Cancer Institute (CBCI), which is part of Presbyterian/ St. Luke's Medical Center situated in Denver and seven other sites across the country."

Answered by AI

What conditions can Tiragolumab be employed to alleviate?

"Tiragolumab is frequently prescribed for chronic lymphocytic leukemia, but also has the potential to help patients who have not responded well to tnf antagonist therapies or had a suboptimal response from prior systemic treatments such as chemotherapy."

Answered by AI
~8 spots leftby Sep 2024